# Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

> **NCT03862768** · NA · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 92 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors
- Surgery

## Interventions

- **PROCEDURE:** surgery
- **DRUG:** Imatinib 400 MG
- **DRUG:** Imatinib escalation
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT03862768
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07
- **Primary completion:** 2021-06
- **Final completion:** 2021-12
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862768, "Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03862768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*